We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful treatment of a patient with lymphocyte-predominant Hodgkin’s lymphoma with yttrium-90-ibritumomab tiuxetan.
- Authors
Zojer, Niklas; Mirzaei, Siroos; Ludwig, Heinz
- Abstract
Lymphocyte-predominant Hodgkin’s lymphoma (LPHL) is known to be radiosensitive, and radiotherapy often forms part of the treatment of patients with stage III or IV LPHL. In addition, as LPHL is thought to arise from a germinal centre B-cell, and LPHL cells express the B-cell marker CD20 there is a rationale for using anti-CD20 therapies for the treatment of LPHL. We report a 42-yr-old man with stage III B LPLH who underwent successful treatment of LPHL with 90Y-ibritumomab tiuxetan. To our knowledge, this is the first report on the use of an anti-CD20 radiolabeled antibody for the treatment of LPHL.
- Subjects
LYMPHOCYTE transformation; INTERLEUKIN-1; LYMPHOID tissue; IMMUNE system; LYMPHATICS; LYMPH nodes; MEDICAL electronics
- Publication
European Journal of Haematology, 2008, Vol 81, Issue 4, p322
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/j.1600-0609.2008.01107.x